

## Mortality and use of angiotensin converting enzyme inhibitors in Covid 19 disease – a systematic review.

José Pedro L. Nunes<sup>1,2</sup>

1. Faculdade de Medicina, Universidade do Porto, Porto, Portugal

2. Department of Cardiology, Centro Hospitalar Universitário São João, Porto, Portugal

Correspondence: JPL Nunes, associate professor, Faculdade de Medicina, Universidade do Porto, Alameda Prof. Hernani Monteiro, 4200 Porto, Portugal. (orcid.org/0000-0001-6739-0304) [jplnunes@med.up.pt](mailto:jplnunes@med.up.pt)

### Abstract

**Background.** Interest exists concerning the use of angiotensin converting enzyme inhibitors (ACEi) in patients with Covid-19 disease.

**Objectives.** To perform a systematic review on mortality associated to the use of ACEi in patients with Covid 19 disease.

**Methods.** Search in Medline (PubMed) and in ISI Web of Knowledge; use of other sources.

**Results.** A total of 19 articles were evaluated. Three studies were selected and used to produce the meta-analyses. These three studies involved a total number of 653 patients treated with ACEi and 3728 not treated with ACEi. Increased mortality was seen in association to the use of ACEi in the context of Covid-19 disease (ACEi users versus non-users; fixed effects; odds ratio, 1.49; 95% confidence interval [CI], 1.18 to 1.87; P=0.001). When compared to mortality in patients treated with angiotensin receptor blockers, mortality of patients treated with ACEi was not significantly different (odds ratio, 0.98; 95% confidence interval [CI], 0.74 to 1.30; P=0.91).

**Conclusions.** ACEi use could act as a marker of increased mortality risk in patients with Covid-19 disease. The data now presented do not prove a causal relation but argue in favor of carrying out clinical trials studying ACEi in Covid-19 patients, in order to establish the safety of ACEi use in this context.

**Key Words:** Mortality; angiotensin converting enzyme inhibitors; Covid-19; systematic review.

## **Introduction**

An epidemic of viral disease caused by a new Coronavirus, Sars-Cov-2, is currently underway in most regions of the world. There is interest concerning angiotensin converting enzyme inhibitors (ACEi) use in this context, since the virus appears to interact with the angiotensin converting enzyme type 2 (ACE2) <sup>1</sup>.

Although ACEi and angiotensin receptor blockers are sometimes evaluated together, they do not have a common mechanism of action, and therefore a separate evaluation of ACEi use in this context may be of interest. In the present report, a systematic review was carried out, looking at published reports studying the association between ACEi use and mortality in patients with Covid-19, the disease caused by the new Coronavirus. The aim of the study was to use currently available data to tentatively evaluate if a relation exists between ACEi use and patient mortality in this context.

## **Methods**

### Search strategy

The study started with a search on Medline (PubMed) database, using the query “Covid-19” AND “ACE inhibitor” AND “mortality”. The search took place on May 9, 2020, and no articles were excluded based on publication date. The query resulted in 4 articles being found. A further search was carried out in a second database, ISI Web of Knowledge, with the same query, in the same date, yielding 2 articles (Figure 1, prepared in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement). Further additional studies were identified in other relevant sources (Figure 1).

### Inclusion criteria

Only human studies with original data were included.

### Exclusion criteria

Excluded were: mechanistic studies; animal studies; case reports; editorials; review papers; study protocols; duplicate studies, if found; systematic reviews and/or meta-analyses; guidelines; genetic or pathological studies.

### Statistical analysis

Meta-analysis was carried out by using the Comprehensive Meta-analysis Software, V.2.0 (Biostat, New Jersey, USA). Fixed effects analyses were carried out, given the lack of significant heterogeneity of the data ( $I^2 < 50$ ). Mortality was the only parameter under study, and the odds ratio was calculated. A level of significance of 0.05 was used.

### Quality assessment of studies and data extraction

Global article quality assessment was carried out according to the method used by Haffar *et al.*, concerning the articles used for the meta-analyses <sup>2</sup>.

### **Results**

A total of 19 articles were identified and selected for further study. One report had no fatalities in one of the groups, making these data unsuitable to be used by the meta-analysis software <sup>3</sup>. One further report did not include the number of deaths <sup>4</sup>. A British report lacked specific data on ACEi <sup>5</sup>. Other articles also failed to include the data of interest for the present purpose <sup>6-14</sup> - and this was the major reason to exclude reports from entering meta-analyses. One article, initially selected, was retracted by the authors on June 4, 2020, and was therefore excluded.

Three studies were used to produce the meta-analyses <sup>15-17</sup> (Figures 2 and 3). These three studies involved a total number of 653 patients treated with ACEi and 3728 not treated with ACEi. The main results concerning ACEi use and mortality are presented in Table 1. Two reports presented data concerning only hypertensive patients, whereas the third did not (Table 1).

Increased mortality was seen in association to the use of ACEi in the context of Covid-19 disease (ACEi users versus non-users; fixed effects; odds ratio, 1.49; 95% confidence interval [CI], 1.18 to 1.87; P=0.001; Figure 2).

When compared to mortality in patients treated with angiotensin receptor blockers, mortality of patients treated with ACEi was not significantly different, (odds ratio, 0.98; 95% confidence interval [CI], 0.74 to 1.30; P=0.91) (Figure 3).

The population studied in two reports had a mean or median patient age over 60 years (Table 1). Overall mortality also differed when the three reports were compared, with mortality rates of 8.18% and 20.99% as extreme values (Table 1).

The three reports used for the meta-analyses were evaluated for global quality, and the results are presented in the Supplementary Table <sup>2</sup>.

## Discussion

In the present report, a systematic review was carried out, concerning the use of ACEi and a possible association to a change in mortality in Covid-19 disease. Only observational reports were found, with no clinical trial data. ACEi use was associated to increased mortality in the setting of Covid-19 disease. This finding is at odds with the report describing favorable results for ACEi in the context of Covid-19, by Ip *et al.*, authors who stated that mortality rates were lower for hypertensive patients prescribed ACEi <sup>4</sup>.

Rossi *et al.* indicate a numerical increase in mortality with previous ACEi use, although the authors carried out a data adjustment for age, sex and Charlson Comorbidity Index, and state that “previous use of ACE inhibitors has no effect on risk of death (HR 0.97, 95% CI 0.69 to 1.34)”

<sup>16</sup>.

Richardson *et al.* also show a numerical increase in mortality with ACEi use <sup>15</sup>.

ACEi use could act as a marker of increased mortality risk in patients with Covid-19 disease – even if not causally related. ACEi use could act as a proxy for the presence of arterial

hypertension, and perhaps also for the presence, in patients with arterial hypertension, of further medical conditions with an increased mortality risk – such as heart failure, chronic kidney disease, coronary artery disease or atrial fibrillation <sup>18</sup>.

Arterial hypertension has been shown to act as a marker of increased mortality risk in Covid-19 disease <sup>19</sup>. The age difference seen in the populations studied by the various authors could modulate the effects of ACEi use in this context. Aging is associated to an increased low grade chronic inflammatory state <sup>20</sup>, decreased muscle mass, increased adiposity and a state of immune dysregulation. In Covid-19 disease, an increase in inflammatory mediators is seen in patients with more severe disease <sup>21</sup>. Increasing age is a known major factor for mortality in Covid-19 disease <sup>21</sup>.

A number of reports presented data on ACEi and/or ARB use in Covid-19 patients. Feng *et al.* reported on 476 patients from China, and stated that “more patients were taking angiotensin converting enzyme inhibitors/ angiotensin II receptor blockers in the moderate group than in the severe and critical groups” <sup>8</sup>. Huang *et al.* reported on 50 hospitalized hypertension patients, and stated that there was no significant difference in clinical severity, clinical course and in-hospital mortality between patients either taking or not taking renin-angiotensin system blocking drugs <sup>22</sup>. Zhang *et al.* reported on 1128 adult patients with hypertension, and stated that “inpatient use of ACEi/ARB was associated with lower risk of all-cause mortality compared with ACEi/ARB nonusers” <sup>9</sup>. These authors used adjusted data, ARB users were in greater number (157 patients) than ACEi users (31 patients) and 34% of patients with hypertension did not receive antihypertensive drugs during hospitalization <sup>9</sup>.

Bean *et al.* reported on 1200 patients from the United Kingdom, and 399 Covid-19 patients were taking ACEi or ARB <sup>5</sup>. The primary endpoint of death or transfer to a critical care unit was reached less often in this latter group (adjusted data).

Mancia *et al.* reported on 6272 Covid-19 patients from Italy, as well as on a control population <sup>7</sup>. The authors showed that both ARB and ACEi were more frequently prescribed in case patients than in controls. After adjustment, ARB and ACEi had no significant association with the risk of Covid-19 disease. Bravi *et al.* reported on 1603 patients, and found no association between disease severity and treatment with ARB and/or ACEi <sup>10</sup>.

Argenziano *et al.* reported on 1000 American Covid-19 patients. Hypertension was seen in 60.1% of patients, and 28.4% of patients were taking either ACEi or ARB. Reynolds *et al.* reported on 5894 Covid-19 patients, including 2573 hypertensive patients <sup>6</sup>. The authors found no association between medication class and either an increased likelihood of a positive test or of severe illness.

### **Limitations**

Limitations of the present report are very important. Not only are all the data reviewed of an observational character, but significant heterogeneity exists when the different reports are compared (as shown in Table 1). Several types of bias could exist in the reports under study.

Significant differences exist between mortality rates associated to Covid-19 disease in different countries. The same happens with patterns of anti-hypertensive drug use.

### **Conclusions**

In conclusion, ACEi use could act as a marker of increased mortality risk in patients with Covid-19 disease. The data now presented do not prove a causal relation but argue in favor of carrying out clinical trials studying ACEi in Covid-19 patients, in order to establish the safety of ACEi use in this context.

**Funding information.** No funding received for the preparation of this text.

**Conflict of interest statement.** None to report.

## References

1. Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. *Cell* 2020;181:271-80.e8.
2. Haffar S, Shalimar, Kaur RJ, et al. Acute liver failure caused by hepatitis E virus genotype 3 and 4: A systematic review and pooled analysis. *Liver Int* 2018;38:1965-73.
3. Meng J, Xiao G, Zhang J, et al. Renin-angiotensin system inhibitors improve the clinical outcomes of COVID-19 patients with hypertension. *Emerging Microbes & Infections* 2020;9:757-60.
4. Ip A, Parikh K, Parrillo JE, et al. Hypertension and Renin-Angiotensin-Aldosterone System Inhibitors in Patients with Covid-19. *medRxiv* 2020:2020.04.24.20077388.
5. Bean DM, Kraljevic Z, Searle T, et al. ACE-inhibitors and Angiotensin-2 Receptor Blockers are not associated with severe SARS-COVID19 infection in a multi-site UK acute Hospital Trust. *Eur J Heart Fail* 2020.
6. Reynolds HR, Adhikari S, Pulgarin C, et al. Renin-Angiotensin-Aldosterone System Inhibitors and Risk of Covid-19. *New England Journal of Medicine* 2020.
7. Mancia G, Rea F, Ludergnani M, Apolone G, Corrao G. Renin-Angiotensin-Aldosterone System Blockers and the Risk of Covid-19. *New England Journal of Medicine* 2020.
8. Feng Y, Ling Y, Bai T, et al. COVID-19 with Different Severities: A Multicenter Study of Clinical Features. *Am J Respir Crit Care Med* 2020;201:1380-8.
9. Zhang P, Zhu L, Cai J, et al. Association of Inpatient Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers With Mortality Among Patients With Hypertension Hospitalized With COVID-19. *Circ Res* 2020;126:1671-81.
10. Bravi F, Flacco ME, Carradori T, et al. Predictors of severe or lethal COVID-19, including Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers, in a sample of infected Italian citizens. *medRxiv* 2020:2020.05.21.20109082.
11. Liu Y, Huang F, Xu J, et al. Anti-hypertensive Angiotensin II receptor blockers associated to mitigation of disease severity in elderly COVID-19 patients. *medRxiv* 2020:2020.03.20.20039586.
12. Liu Y, Yang Y, Zhang C, et al. Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury. *Sci China Life Sci* 2020;63:364-74.
13. Yang G, Tan Z, Zhou L, et al. Angiotensin II Receptor Blockers and Angiotensin-Converting Enzyme Inhibitors Usage is Associated with Improved Inflammatory Status and Clinical Outcomes in COVID-19 Patients With Hypertension. *medRxiv* 2020:2020.03.31.20038935.
14. Zeng Z, Sha T, Zhang Y, et al. Hypertension in patients hospitalized with COVID-19 in Wuhan, China: A single-center retrospective observational study. *medRxiv* 2020:2020.04.06.20054825.
15. Richardson S, Hirsch JS, Narasimhan M, et al. Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area. *JAMA* 2020.
16. Giorgi Rossi P, Marino M, Formisano D, Venturelli F, Vicentini M, Grilli R. Characteristics and outcomes of a cohort of SARS-CoV-2 patients in the Province of Reggio Emilia, Italy. *medRxiv* 2020:2020.04.13.20063545.
17. Li J, Wang X, Chen J, Zhang H, Deng A. Association of Renin-Angiotensin System Inhibitors With Severity or Risk of Death in Patients With Hypertension Hospitalized for Coronavirus Disease 2019 (COVID-19) Infection in Wuhan, China. *JAMA Cardiology* 2020.
18. Williams B, Mancia G, Spiering W, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology (ESC) and the European Society of Hypertension (ESH). *European Heart Journal* 2018;39:3021-104.

19. Cummings MJ, Baldwin MR, Abrams D, et al. Epidemiology, clinical course, and outcomes of critically ill adults with COVID-19 in New York City: a prospective cohort study. *Lancet* 2020.
20. Chung HY, Kim DH, Lee EK, et al. Redefining Chronic Inflammation in Aging and Age-Related Diseases: Proposal of the Senoinflammation Concept. *Aging Dis* 2019;10:367-82.
21. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *Lancet* 2020;395:497-506.
22. Huang Z, Cao J, Yao Y, et al. The effect of RAS blockers on the clinical characteristics of COVID-19 patients with hypertension. *Ann Transl Med* 2020;8:430.



Authors	Population	ACEi users	Non ACEi users	ARB users
Li et al.	Observational single-center case series of the 1178 hospitalized patients with COVID-19 infections at the Central Hospital of Wuhan, China, from January 15 to March 15, 2020. Data reported for 362 patients with arterial hypertension. Median age 55.5 years (interquartile range, 38-67 years). Overall mortality: 11.03% (21.27% for patients with arterial hypertension). Criterion: use of drugs at the time of admission that continued through hospitalization.	35 ACEi users. 28 survivors; 7 non-survivors.	327 non-ACEi users. 257 survivors; 70 non-survivors.	83 ARB users. 68 survivors; 15 non-survivors.
Richardson et al.	Observational case series of 5700 patients with COVID-19 admitted to 12 hospitals in New York. Median age 63 years, (interquartile range 52-75 years). Data reported for patients with arterial hypertension. Overall mortality: 20.99% (28.11% for patients with arterial hypertension). Criterion: home medication at admission.	168 ACEi users. 113 patients discharged; 55 non-survivors.	1198 Non-ACEi users. 869 patients discharged; 329 non-survivors.	245 ARB users. 170 patients discharged; 75 non-survivors.
Rossi et al.	Observational study of all 2653 symptomatic patients who tested positive for SARS-CoV-2 from February 27 to April 2, 2020 in the province of Reggio Emilia. Mean age 63.2 years. Overall mortality: 8.18%. Criterion: use of drugs in previous year.	450 ACEi users. 56 non-survivors.	2203 Non-ACEi users. 161 non-survivors.	368 ARB users. 52 non-survivors.
Meng et al.	Observational study of 476 patients recruited from January 1 to February 15, 2020 at three hospitals in Wuhan, Shanghai and Anhui.	2 ACEi users. 0 non-survivors.	40 non-ACEi users. 1 non-survivor.	14 ARB users. 0 non-survivors.

	Median age of analyzed subjects 64.5 years (interquartile range, 55.8–69.0 years). Data from 42 patients receiving antihypertensive therapy. Overall mortality: 2.38%.			
--	--	--	--	--

Table 1. Major data from the selected papers. ACEi – angiotensin converting enzyme inhibitors. ARB – angiotensin receptor blockers. For references see text.




Figure 1. Flow diagram of studies selection.




Figure 2. Meta-analysis comparing mortality in patients with Covid-19 disease treated or not treated with angiotensin converting inhibitors (ACEi). For references see text. CI – confidence interval.




Figure 3. Meta-analysis comparing mortality in patients under angiotensin converting inhibitors (ACEi) or angiotensin receptor blockers (ARB) in patients with Covid-19 disease. For references see text. CI – confidence interval.